K. Kruntoradova

Cost-Effectiveness Analysis of the Information Technology Aided Relaps Prevention Programme in Schizophrenia (Itareps) in the Czech Republic

References [1] Španiel F, Hrdlička J, Novák T, et al. Effectiveness of the TechnologyAided Programme of Relapse Prevention in Schizophrenia (ITAREPS): A Randomized, controlled, double blind study. J Psychiatr Pract 2012;18:269–80. [2] Komatsu H, Yoshimoto S, Okamura N, et al. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial. Schizophrenia Res 2013;150:240–4. [3] Saha S, Chant D, McGrath J. „A Systematic Review of Mortality in Schizophrenia.“ Arch Gen Psychiatry 64 (2007): 1123-1131. [4] Czech mortality tables. Czech Statistical Office. Available online at [https://www.czso.cz/csu/czso/umrtnostni_tabulky] to 16/10/2015. [5] ITAREPS 2.0: relapse prevention programme of psychotic disorders. Prague 2011. Working material delivered to iHETA and consulted with the authors. [6] Exchange rates, monthly averages. Czech National Bank. Available online at [https://www.cnb.cz/cs/financni_trhy/devizovy_trh/kurzy_devizoveho_trhu/prumerne_mena.jsp?mena=EUR] to 16/10/2015. [7] Harmonized index of consumer price. Eurostat. Available online at [http://ec.europa.eu/eurostat/web/hicp/statistics-illustrated] to 16/10/2015. [8] Graham C, Mauskopf J, Lawson H, Ascher-Svanum H, Bruhn D. „Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia.“ Value in Health 15 (2012): 55–64. [9] The European Mental Health Action Plan. WHO Europe. Available online at [http://www.euro.who.int/__data/assets/pdf_file/0004/194107/63wd11e_MentalHealth-3.pdf?ua=1] to 16/10/2015. BACKGROUND and OBJECTIVES Information technology aided relapse prevention programme in schizophrenia (ITAREPS) is a unique mobile phone-based telemedicine solution (operated via short message service (SMS)) for weekly remote patient monitoring and disease management of psychotic disorders in general, particularly of schizophrenia. It was developed for rapid and targeted recognition of early warning signs of relapse and it improves and speeds up communication between the patient and her/her psychiatrist Quick capture of early signs of relapse allows doctors to immediately adjust the patient’s treatment and keep her in stable condition without relapse (see https://www.itareps. com/en/?c=xx). Evidence from randomized clinical trials (RCTs) suggests that ITAREPS is very effective in decreasing hospitalization schizophrenia relapses [1,2]. Although it is highly effective, it is not reimbursed by some health insurance companies in the Czech Republic. Based on these RCTs, we performed a cost-utility analysis of ITAREPS compared to the treatment of schizophrenia without ITAREPS (non-ITAREPS) in the Czech Republic. This analysis should ideally support reimbursement and decrease the uncertainty related to cost and outcomes of this intervention.

Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic

[1] Rummel, MJ et al.: Bendamustin plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet 381, 1203-1210 (2013). [2] Expert panel conducted for the purposes of the model, available on request. [3] Salles, G. et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. The Lancet 377, 42-51 (2010). [4] Ray, JA et al. An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular NonHodgkin’s Lymphoma in the UK. Value in Health 13, 346-357 (2010). [5] Dewilde, S. et al.: Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin‘s lymphoma in England and Wales. Journal of Medical Economics 17, 111-124 (2014). [6] Czech National Bank. Average from the respective period (January-May 2014). Available online on [https://www.cnb.cz/cs/financni_trhy/devizovy_trh/ kurzy_devizoveho_trhu/prumerne_mena.jsp?mena=EUR] to 6th October 2014. [7] State Institute of Drug Control (SUKL) recommends, based on WHO recommendation, using 3-times GDP per capita as a willingness to pay threshold (see http://www.sukl.cz/file/73935_1_1/, translation available on request). On treatment*

The Impact of Adherence and Development of Neutralizing Antibodies to Interferons β on Treatment of Multiple Sclerosis in the Czech Republic.

1 Steinberg SC et al., Clin Drug Investig. 2010;30(2):89-100 • 2 Clerico M et al. Neurol Sci. 2007 Aug 15;259(1-2):104-8 • 3 Sorensen PS et al. Mult Scler. 2008 Jul;14(6):837-42 • 4 Koch-Henriksen N et al. Mult Scler. 2009 May;15(5):601-5 • 5 Paolicelli D et al. J Neurol. 2013 Jun;260(6):1562-8 • 6 Farrell R et al. Mult Scler. 2008 Mar;14(2):212-8 • 7 Devonshire V et al., Eur J Neurol. 2011 Jan;18(1):69-77 • 8 Hegen H et al., Mult Scler. 2012 May;18(5):610-5 • 9 Jacobs LD et al., Ann Neurol. 1996 Mar;39(3):285-94 • 10 PRISMS Study Group., Lancet. 1998 Nov 7;352(9139):1498-504 • 11 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, Neurology. 1995 Jul;45(7):1277-85 • 12 Devonshire V et al., Lancet Neurol. 2012 May;11(5):420-8 • 13 Johnson KP et al., Neurology. 1995 Jul;45(7):1268-76 • 14 Polman CH et al., N Engl J Med. 2006 Mar 2;354(9):899-910 • 15 Tappenden P et al., ScHARR, University of Scheffield, 2001 • 16 State Institute of Drug Control. Medicinal products database, 2013 • 17 Vocelka M et al., Farmakoekonomika. 2012;1:29-33 • 18 Tan H et al., Adv Ther. 2011 Jan;28(1):51-61 • 19 Blahova Dusankova J et al., Mult Scler. 2012 May;18(5):662-8 • 20 General Health Insurance Company of the Czech Republic., List of medical services, 2013 • 21 IMS Health Inc., IMS total market sales data, 2013 • 22 Halpern R et al., Patient Prefer Adherence. 2011 Jan 20;5:73-84 • 23 Treadaway K et al., J Neurol. 2009 Apr;256(4):568-76 • 24 Meluzínová E., Zdravotnické noviny. 012;61(3): 20-21 • 25 Farrell RA et al., J Interferon Cytokine Res. 2010 Oct;30(10):715-26 • 26 Hutchinson M et al., Curr Med Res Opin. 2014 Apr;30(4):613-27 CONCLUSIONS

Cost-Effectiveness Analysis of Atorvastatin Compared to Simvastatin in the Prevention of Cardiovascular Diseases in the Czech Republic

1Institute of Health Economics and Technology Assessment, Prague, Czech Republic 2Faculty of Pharmacy, Charles University in Prague, Czech Republic 3Third Medical Faculty, Charles University in Prague, Czech Republic 4Faculty of Biomedical Engineering, Czech Technical University in Prague, Czech Republic COST-EFFECTIVENESS ANALYSIS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLIC